SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending following its announcement of a record date for a digital token initiative, drawing significant community discussion around its venture into crypto. This attention is amplified by escalating geopolitical rhetoric, including commentary on Greenland and new tariff threats, which is heavily influencing market sentiment and broader economic concerns. The stock continues to be a focal point for politically charged narratives, with both enthusiastic supporters and market participants expressing strong, polarized views.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending due to regulatory clarity for ANKTIVA's resubmission for papillary bladder cancer, requiring no new clinical trials, coupled with expanding international approvals. The community is actively discussing the potential for a significant short squeeze, driven by high short interest and exceptional volume, as many investors embrace the long-term "cancer cure" narrative. This optimism persists even as the broader market faces headwinds, highlighting IBRX's standout performance and promising pipeline.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community closely follows its ongoing interactions with the FDA regarding the Biologics License Application for its Duchenne muscular dystrophy treatment, deramiocel, and the forthcoming submission of the full HOPE-3 clinical study report. Sentiment is divided, with many expressing strong bullishness and anticipating significant upside potential, while others voice concerns over perceived delays and discuss potential market manipulation, as analysts reiterate positive ratings for the company.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following a significant non-exclusive licensing deal with Pfizer for its Matrix-M adjuvant, a move widely seen as powerful validation for the platform technology beyond its initial COVID application. The community is actively debating whether this partnership signals NVAX's evolution into a royalty-generating company and if high short interest will trigger a substantial upward move, despite some expressing frustration over the immediate market reaction amidst a broader downturn.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

Top Wealth Group Holding Ltd. is currently trending due to news of a strategic acquisition and a recent public offering that sparked extreme volatility. The community is sharply divided between anticipating massive upside driven by its low float and projected profitability, and expressing caution over its significant price swings. Traders are actively debating if this presents a compelling buying opportunity or a cautionary tale, drawing parallels to other high-momentum low-float stocks.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to highly positive Phase 1 clinical trial results for its drug, soquelitinib, in treating moderate to severe atopic dermatitis. This early data, especially in patients resistant to other treatments, is fueling community excitement about its potential as a significant new option in a large market, with discussions also revolving around the possibility of strategic partnerships or a buyout, alongside concerns about the drug's early development stage.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital (NUAI) is trending following its acquisition of Texas Critical Data Centers and a new partnership to co-develop a large-scale AI data center campus in West Texas. The community is actively discussing an anticipated hyperscaler tenant announcement, which many believe could significantly boost the stock. Despite some lingering concerns over past allegations, investors are keenly focused on the company's strategic advancements in the high-demand AI infrastructure sector.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is trending as the community eagerly discusses its strategic expansion plans, including a new rare earth facility in France backed by government support, alongside advancements at its Stillwater magnet plant. These developments are viewed within the broader context of increasing geopolitical tensions and a global push for rare earth independence from traditional suppliers, though some express frustration over consistent price resistance and perceived manipulation compared to sector peers.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing an unprecedented surge driven by escalating AI demand for memory chips, leading to a global supply shortage. This momentum is reinforced by significant capacity expansion initiatives, including a Taiwan fab acquisition and a New York megafab groundbreaking, alongside notable insider buying and analyst upgrades. While many celebrate its "monster" rally and market-leading strength, a segment of the community remains cautious, labeling it an "overextended" "bubble stock" due for a pullback.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is a major talking point as geopolitical tensions escalate over the US's pursuit of Greenland and potential tariffs, prompting a Danish pension fund to divest from US Treasuries citing credit risk concerns. The community remains sharply divided, with some fearing broader international divestment and higher yields while others anticipate eventual rate cuts amid a slowing economy and increased Fed intervention.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GH Research (NASDAQ:GHRS) Stock Price Down 9.2% - Should You Sell?

GH Research (NASDAQ:GHRS) Stock Price Down 9.2% - Should You Sell...

GH Research (NASDAQ:GHRS) Shares Gap Up - Time to Buy?

GH Research (NASDAQ:GHRS) Shares Gap Up - Should You Buy...

Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday

FDA Lifts Hold On GH Research's Depression Drug Trial After Two Years

The FDA lifted its clinical hold on GH Research's GH001 after Phase 2b data showed rapid, durable benefits in treatment-resistant depression, clearing the path toward Phase 3 trials planned for...

<ul class="summary-bullets"><li>The company is targeting the initiation of Phase 3 clinical trials this year.</li><li>In an update about the GH001 Phase 2b clinical trial, GH Research stated that the primary endpoint was met with a highly significant placebo-adjusted reduction from baseline.</li><li>It added that there were no treatment-related serious adverse events during the six-month trial duration.</li></ul>GH Research PLC (GHRS) shares gained more than 42% in Monday’s opening session after the company announced a positive development in its depression treatment trials.GH Research announced on Monday that the U.S. Food and Drug Administration (FDA) had lifted the clinical hold on GH001, its lead product candidate.<h2 class="st-heading-2">FDA Lifts Hold</h2>In a filing with the U.S. Securities and Exchange Commission (SEC), GH Research stated that the FDA has cleared GH001 for a clinical investigation in the United States, subject to the enrollment of participants. The company is targeting the initiation of Phase 3 clinical trials this year.“We continue to expect initiation of our global pivotal program in 2026. We look forward to meeting with the FDA to align on the design for the pivotal Phase 3 program,” said GH Research CEO Dr. Velichka Valcheva.GH Research is a Dublin, Ireland-based clinical-stage biopharmaceutical company, focusing on the development of proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD).<h2 class="st-heading-2">GH001 Phase 2b Data</h2>In an update about the GH001 Phase 2b clinical trial, GH Research stated that the primary endpoint was met with a highly significant placebo-adjusted reduction from baseline.The company stated that a full analysis of the open-label extension (OLE) phase showed a 73% remission rate at six months with infrequent treatment visits and no mandated psychotherapeutic intervention.Further, the company said that a safety analysis showed 100% of the patients from the double-blind (DB) part continued in the OLE. It added that there were no treatment-related serious adverse events during the six-month duration of the trial.OLE is a phase of clinical trials in which participants may continue receiving the experimental treatment after completing the initial controlled phase.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits regarding&nbsp;<a href="https://stocktwits.com/symbol/GHRS">GH Research</a> trended in the ‘extremely bullish’ territory at the time of writing.&nbsp;One Stocktwits user expects GHRS stock to rally further when the markets open.<stembedurl>https://stocktwits.com/BLD33/message/640804183</stembedurl><a href="https://stocktwits.com/symbol/GHRS">GHRS stock</a> is up 48% year-to-date and 108% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-dvlt-stock-gaining-today/cmxMnTMR4bM">Why Is DVLT Stock Gaining Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the GH Research logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Is GHRS Stock Rising Today?

GH Research stated that the FDA has cleared GH001 for a clinical investigation in the U.S.

Equity

GH Research (NASDAQ:GHRS) Receives Buy Rating from Needham & Company LLC

Needham & Company LLC reiterated a "buy" rating and set a $19.00 price objective on shares of GH Research in a research note on Monday...

NextEra Energy, GH Research And 3 Stocks To Watch Heading Into Monday

Stock Market Today: S&P 500, Nasdaq Futures Rise, WTI Fluctuates Following US Strike On Venezuela GH Research, Vertiv Holdings, Nukkleus In Focus

U.S. stock futures rose in the first full trading week of the year on Monday after closing mixed on Friday. Futures of major benchmark indices were higher.read more...

Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket

<ul class="summary-bullets"><li>GH Research is scheduled to update on the FDA status of GH001 and outline its global Phase 3 plans for treatment-resistant depression on Monday.</li><li>The update follows the company’s submission of a complete response to the FDA after a prior clinical hold.</li><li>Progress across competing psychedelic-based depression programs has increased focus on the stock.</li></ul>Shares of GH Research PLC drew increased retail attention on Monday ahead of a scheduled update on its FDA Investigational New Drug application for GH001, the company’s inhaled therapy for treatment-resistant depression, and its plans for a global Phase 3 program, due at 7:00 a.m. EST.<h2 class="st-heading-2">Phase 3 Program And FDA Update In Focus</h2>The update follows the company’s June disclosure that it submitted a complete response to the FDA addressing a previously announced clinical hold on the IND. At the time, GH Research said the submission included completed toxicology studies and comprehensive responses to the agency’s requests, adding that it had worked closely with regulators and submitted the response ahead of schedule.<h2 class="st-heading-2">GH001 Data Anchors Development Path</h2>GH001 is GH Research’s lead experimental therapy, delivered through a proprietary inhalation system and designed to treat patients with treatment-resistant depression, a condition where standard antidepressants have failed.In February 2025, the company reported results from a Phase 2b study involving 81 patients. Those treated with GH001 showed a significant improvement in depression symptoms within eight days, with scores on a standard clinical scale falling by an average of 15.5 points more than placebo. The difference was statistically significant.Over half of the patients receiving GH001 achieved remission by Day 8, compared with none in the placebo group. The company said all secondary study goals were met, and the treatment was well tolerated, with no serious adverse events reported during the blinded phase of the trial.Longer-term follow-up data showed sustained benefits. Among patients who completed six months of follow-up, nearly 78% remained in remission, with most requiring only a small number of additional treatments. As of late January 2025, the company reported no serious safety issues during this extended period.<h2 class="st-heading-2">Psychedelic Race Intensifies</h2>In November, H.C. Wainwright lowered its price target on GH Research to $35 from $40 while maintaining a ‘Buy’ rating, citing competitive momentum from programs such as Atai Beckley’s BPL-003 and AbbVie’s GM-2505, as well as the prior FDA hold.In October, Needham initiated coverage with a ‘Buy’ rating and a $19 price target, citing GH001’s Phase 2 efficacy and remission data and estimating potential U.S. sales of $1.9 billion by 2035.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for GH Research was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:968/143;" src="https://news.stocktwits-cdn.com/ghrs_ss_png_215c6b80c9.webp" alt="ghrs ss.png" width="968" height="143"><figcaption>GHRS sentiment and message volume as of January 5| Source: Stocktwits</figcaption></figure>One user grouped GH Research alongside names like Disney, Marathon Digital, Critical Metals and Navitas Semiconductor, saying the stock continues to sit within a cluster of “hot themes” across the market.<stembedurl>https://stocktwits.com/JoyceFernandez/message/640797658</stembedurl>Another user said they plan to sell part of their position around the FDA update to lock in gains and hold the rest into the next company update later in the quarter.<stembedurl>https://stocktwits.com/NoobFriendly/message/640797043</stembedurl><a href="https://stocktwits.com/symbol/GHRS">GH Research’s stock</a> has risen 89% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

GH Research Stock Grabs Retail Spotlight Ahead Of FDA Update On Depression Treatment

GH001 showed symptom improvement, high remission rates, and sustained benefits in a Phase 2b trial for treatment-resistant depression.

GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients of psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.

Current Price	$16.20
Prev Close	$16.99
Open	$16.36
Dividend Yield	0.00%
50-Day Moving Average	$14.18
Beta	0.82
Avg. Volume	227,953.50
PE Ratio	-23.23

52-Week High	$20.50
52-Week Low	$7.98
Market Capitalization	$1.05B
EPS (Annual)	-$0.7488
Price to Book	3.62
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

GHRS
GH Research PLC

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GHRS News

GHRSGH Research PLC